Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02270814 · ClinicalTrials.gov registry record · Phase 2
Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma
A Phase 2 study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma, sponsored by Washington University School of Medicine.
- Active
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
- 5
- Study locations
NCT02270814: Active Phase 2 study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma, sponsored by Washington University School of Medicine.
NCT02270814 is a Phase 2 study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 74 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (72% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02270814, a Phase 2 study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma, is active but no longer recruiting, sponsored by Washington University School of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this research study is to look at the effect of a treatment regimen called CACTUX on head and neck cancer. The CACTUX regimen is a combination of three drugs called cisplatin, nab-paclitaxel, and cetuximab (although carboplatin may be given in place of cisplatin if participants have previously had problems receiving cisplatin). The use of nab-paclitaxel in this combination is different from routine care, in which a drug called 5FU is often given instead, but the investigators group has conducted previous research where the investigators incorporated nab-paclitaxel into routine treatment with cisplatin, 5FU, and cetuximab. The investigators are looking at the incidence of side effects with the CACTUX regimen as well as response of the disease and health status.
Primary Outcome
PFS is defined as the time from randomization to first radiologic confirmation of disease progression, or death from any cause.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- BIOLOGICAL Cetuximab
- DRUG nab-paclitaxel
Study Locations (5)
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Mississippi
- University of Mississippi Medical Center - Jackson
Missouri
- Washington University School of Medicine - St Louis
North Dakota
- Sanford Roger Maris Cancer Center - Fargo
South Dakota
- Sanford Cancer Center Oncology Clinic and Pharmacy - Sioux Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2015-02-02 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
What the registry record for NCT02270814 still lists
NCT02270814 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 74 participants, a relatively small participant target, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (72% lower).
The record links to 3 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.
NCT02270814 lists 5 locations in 5 states (Arkansas, Mississippi, Missouri).
Frequently Asked Questions
What is clinical trial NCT02270814 about?
NCT02270814 is a clinical study titled "Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma". The purpose of this research study is to look at the effect of a treatment regimen called CACTUX on head and neck cancer. The CACTUX regimen is a combination of three drugs called cisplatin, nab-paclitaxel, and cetuximab (although carboplatin may be given in place of cisplatin if participants have p...
What is the current status of trial NCT02270814?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2015-02-02. Estimated completion is 2026-06-30.
What conditions does trial NCT02270814 study?
This clinical trial studies the following conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Head and Neck.
What interventions are being tested in trial NCT02270814?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Cetuximab (BIOLOGICAL), nab-paclitaxel (DRUG).
Who is sponsoring clinical trial NCT02270814?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02270814 being conducted?
This trial has 5 study locations across Arkansas, Mississippi, Missouri, North Dakota, South Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02270814's enrollment target sits among peer trials
74 103rd of 250 higher than 148 of 250 other Head and Neck Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase II Panitumumab-IRDye800 in Head & Neck Cancer
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
RECRUITING · Phase 2
-
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422731 · 74 participants · Early Phase 1
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
- NCT03804853 · 74 participants · NA
Rehabilitation Following Reverse Total Shoulder Arthroplasty
- NCT04065776 · 74 participants · NA
Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
- NCT04771156 · 74 participants · Phase 4
Ketorolac in Palatoplasty
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI